Intermediate-high Risk
1 clinical trials · Condition
◉ Watch Intermediate-high Risk
| Record | Firm | Date |
|---|---|---|
| Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism (NCT02946944) | Meshalkin Research Institute of Pathology of Circulation | 2016-10-01 |
Track Intermediate-high Risk automatically
Every clearance here is in the API, with alerts when new ones post.